GH axisResearch Market

GHRP-6

A classic growth hormone secretagogue that remains common in peptide-market catalogs despite limited mainstream clinical relevance.

Growth HormoneSecretagogueResearch Market

Also appears in: Performance

Price compare
24 tracked offers across 24 vendors · 6 dosages
Best trust-adjusted value: Peptuvia · Strong trust · $0.60/mg
From
$0.60/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

-76.2%vs. Aug 10
Current low$0.60/mg
Market median$3.90/mg
Current coverage16 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when GHRP-6 crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence23 certificate records mentioning this compound or product name11 provider-linked · 19 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
GH axis / secretagogue research

Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 0 trials · 636 PubMed results

Preclinical
Research evidence

Current evidence for GHRP-6 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

GHRP-6 has no clinical trials that name it and 636 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
The Journal of Clinical Endocrinology & Metabolism · 190 citationsBlocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.The Journal of Clinical Endocrinology & Metabolism · 147 citationsMassive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.European Journal of Pharmacology · 142 citationsComparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitroCase ReportsAnterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.Journal ArticleGhrelin impairs embryo development after ovarian hyperstimulation.Journal ArticleThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What GHRP-6 is

GHRP-6 is a growth hormone secretagogue that has long circulated in bodybuilding and research-market communities. It is one of the foundational names in the GH peptide niche.

Why it matters

Even if newer categories attract more attention today, GHRP-6 helps explain the older structure of the peptide market and why GH-oriented compounds still occupy a separate lane.

Regulatory context

GHRP-6 is not FDA approved in the United States for performance or GH optimization use.

Practical reading note

This is a category where historical community use often gets mistaken for modern clinical legitimacy, and the two are not the same thing.